×

Erasca’s pill shrinks hard-to-treat pancreatic and lung tumors in early-stage trial

By Thomson Reuters Nov 20, 2026 | 6:49 AM

Nov 20 (Reuters) – Erasca said on Friday its experimental cancer pill shrank tumors in many patients with advanced pancreatic ​and lung cancers in an early-stage ‌trial.

• Of 25 patients with pancreatic cancer taking a 32 mg daily dose of the drug, ERAS-0015, 44% saw tumors shrink significantly, Erasca said

• In ‌patients ​with the two most ⁠common genetic variations of ⁠the disease, the response rate jumped to 69%

• In lung cancer, 60% of five patients who had already received immunotherapy ​and chemotherapy responded to the drug

• ERAS-0015 acts as a “molecular glue” that blocks ⁠faulty RAS proteins, effectively ⁠shutting down vital signals that cancer ​cells need to grow and multiply

• RAS proteins ​act as ‘on-off’ switches for cell growth, ‌but can get stuck in the ‘on’ position when they mutate, driving uncontrolled growth of many common and deadly cancers

• Erasca said ⁠the treatment was generally well tolerated

• The company had earlier reported one death from lung inflammation in ⁠a patient ‌taking a 24 mg dose ⁠of the drug

• Erasca plans ​to ‌start late-stage clinical trials in both ​pancreatic and ⁠lung cancers in 2027

• The company said it would also test the drug alongside a second experimental treatment, ERAS-4001, starting in 2027

(Reporting by Kamal Choudhury in Bengaluru; Editing by ​Jonathan Ananda)